In the third quarter of 2025, Bruker reported adjusted earnings per share of US$0.45, topping estimates even as earnings fell 25% year over year.

The company simultaneously cut its full-year 2025 guidance, now expecting revenues of US$3.41–US$3.44 billion and adjusted EPS of US$1.85–US$1.90, highlighting tension between near-term cost control and a softer outlook.

We’ll now examine how Bruker’s lowered full-year revenue and earnings guidance affects its longer-term investment narrative and risk profile.

Outshine the giants: these 26 early-stage AI stocks could fund your retirement.

To own Bruker, you need to believe that demand for its high end analytical and life science tools eventually improves, and that current earnings pressure is temporary. The Q3 2025 earnings beat alongside weaker full year guidance reinforces that the key near term catalyst is a funding and order recovery, while the biggest risk remains that softer demand and reliance on cost control continue to weigh on margins and visibility.

The most relevant recent announcement here is Bruker’s lowered full year 2025 guidance to US$3.41–US$3.44 billion in revenue and adjusted EPS of US$1.85–US$1.90. This tighter outlook directly connects to the risk that earnings lean more on cost savings than on organic growth, which could leave results sensitive if academic and biopharma spending stay constrained longer than expected.

But investors should also be aware that if funding headwinds in US and China persist beyond 2025, then...

Read the full narrative on Bruker (it's free!)

Bruker’s narrative projects $3.8 billion revenue and $404.1 million earnings by 2028.

Uncover how Bruker's forecasts yield a $48.83 fair value, in line with its current price.

Five members of the Simply Wall St Community currently see Bruker’s fair value anywhere between US$31.30 and US$75.00 per share, underscoring how far opinions can diverge. When you weigh those views against the risk that weak research funding and softer guidance keep pressuring Bruker’s growth and earnings mix, it becomes even more important to compare several perspectives before deciding what the stock’s long term potential really looks like.

Explore 5 other fair value estimates on Bruker - why the stock might be worth 35% less than the current price!

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

A great starting point for your Bruker research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Our free Bruker research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bruker's overall financial health at a glance.

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

We've found 15 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Rare earth metals are the new gold rush. Find out which 36 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BRKR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com